Prescription of lipophilic statins to Alzheimer’s disease patients: some controversies to consider
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Elisa Biondi
- چاپ و سال / کشور: 2011
Description
Alzheimer’s disease (AD) is the most common disorder causing cognitive decline in old age. It is a progressive and irreversible neuropathology with a diagnosis often missed or delayed. Cholesterol represents an important determinant of the physical state of biological membranes and in AD brains, specific changes in its membrane-ordering and Raft-organizing effects take place. A recent publication shows downregulation of Seladin-1 (selective Alzheimer’s disease indicator, also called DHCR24), which catalyzes the last step of cholesterol biosynthesis in affected neurons in AD. Postmortem analysis of AD brains revealed a loss in membrane cholesterol content and this finding makes the therapeutical use of statins (especially the lipophilic ones) quite a lot controversial. Some clinical studies suggest that risk of Alzheimer’s disease is substantially reduced in users of statins; however, because these studies are not randomized trials, they provide insufficient evidence to recommend statin family therapy
Neurol Sci (2011) 32:195–201 DOI 10.1007/s10072-010-0440-0 Received: 13 October 2009 / Accepted: 22 September 2010 / Published online: 19 October 2010
